|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | RTOG 0211:a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients显示文摘PURPOSE: To determine the safety and efficacy of gefitinib,an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,in combination with radiation for newly diagnosed glioblastoma(GBM) patients.METHODS AND MATERIALS: Between March 21,2002,and May 3,2004,Radiation Therapy Oncology Group(RTOG) 0211 enrolled 31 and 147GBM patients in the phase 1 and 2 arms,respectively.Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy(RT) and continued post RT for 18 months or until progression.Tissue microarrays from 68 cases were analyzed for EGFR expression.RESULTS: The maximum tolerated dose(MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs(non-EIAEDs).All patients in the phase 2 component were treated at a gefitinib dose of 500 mg;patients receiving EIADSs could be escalated to 750 mg.The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal.Median survival was 11.5 months for patients treated per protocol.There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone,matched by RTOG recursive partitioning analysis(RPA) class distribution.Younger age was significantly associated with better outcome.Per protocol stratification,EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients.CONCLUSIONS: The addition of gefitinib to RT is well tolerated.Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone. | Chakravarti A Wang M Robins HI Lautenschlaeger T Curran WJ Brachman DG Schultz CJ Choucair A Dolled-Filhart M Christiansen J Gustavson M Molinaro A Mischel P Dicker AP Bredel M Mehta M | 2013 | 中国神经肿瘤杂志2013，11，1： | 8 |
| 2 | Whole body hyperthermiainductin of soulubel tumor necrosis factor receptros;implications forrheumatoid diseas显示文摘 | Robins HI Grosen E Katschinski DM el al | 1999 | J Rheumatol1999，26，12： | 1 |
| 3 | Therapeutic advances in malignant glioma:current status and future prospects显示文摘 | Robins HI Lassman AB Khuntia D | 2009 | Neuroimaging Clin N Am2009，19，4： | 1 |
| 4 | Neuroendocrine changes in patients undergoing whole body hyperthermia显示文摘 | Robins HI Kalin NH Shelton SE | 1987 | Int J Hyperthermia1987，3，2： | 1 |
| 5 | Whole body hyperther- Mia in the treatment of neoplase diseade 显示文摘 | Robins HI Hugander A Cohen JD | 1989 | Radiol Clin Nor-Th Am1989，27，3： | 1 |
| 6 | Systemic hyperthermia and ICE chemotherapy for sarcoma patients:rationale and clinical status显示文摘 | Wiedemann GJ Robins HI Katschinski DM | 1997 | Anticancer Res1997，17，4： | 1 |
| 7 | A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozalomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320显示文摘 | Sperduto PW Wang M Robins HI | 2013 | Int J Radiat Oncol Biol Phys2013，85，： | 1 |
| 8 | Systemic hyperthermia and ICE chemotherapy for sarcoma patients; rationale and clinical status 显示文摘 | Wiedemann GJ Robins HI Katschinski DM | 1997 | Anticancer Res1997，17，4： | 1 |
| 9 | Whole body hyperthermia:simple complexitie显示文摘 | Robins HI Longo W | 1999 | Intensive Care Med1999，25，9： | 1 |
| 10 | Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status显示文摘 | Wiedemann GJ Robins HI Katschinski DM | 1997 | Anticancer Res1997，17，： | 1 |
| 11 | Pulsed reduced dose-rate radiotherapy: case report, a novel re-treatment strategy in the mana- gement of recurrent glioblastoma multiforme显示文摘 | Cannon GM Tome WA Robins HI | 2007 | J Neurol Oncol2007，83，3： | 1 |
| 12 | Systemic hyperthermia and ICE chemotherapy for sarcoma patients; rationale and clinical status 显示文摘 | Wiedemann GJ Robins HI Katscbinski DM | 1997 | Anticancer Res1997，17，4： | 1 |
| 13 | Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region显示文摘 | Richards GM Tome WA Robins HI | 2009 | Breast Cancer Res Treat2009，114，2： | 1 |
| 14 | A phase 3 trim of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for nonsmall cell lung cancer and 1 to 3 brain metastases radiation therapy on- cology group 0320 显示文摘 | Sperduto PW Wang Meihua Robins HI | 2013 | Radiat Oncol Biol Phys2013，85，5： | 1 |
| 15 | Whole body hyperthermia in the treatment of neoplaastic disease显示文摘 | Hugander A Cohen JD | 1989 | Radiol Clin North Am1989，27，3： | 1 |
| 16 | A Phase Ⅱ study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants:A North American Brain Tumor Consortium report显示文摘 | Chang SM Kuhn JG Robins HI | | 0，，02： | 1 |
| 17 | Rise in plasma beta-endorphin,ACTH,and cortisol in cancer patients undergoing whole body hyperthermia显示文摘 | Robins HI Kalin NH Shelton SE | | 0，，09： | 1 |
| 18 | Systemic hyperthermia and ICE chemotherapy for sarcoma patients: Rationale and clinical status显示文摘 | Wiedemann GJ Robins HI Katschinski DM | 1997 | Anticancer Res1997，17，4： | 1 |
| 19 | Systemic hyperthermia and ICE chemotherapy for sarcoma patients:rationale and clinical status显示文摘 | Wiedemann GJ Robins HI Katschinski DM | 1997 | Anticancer Res1997，17，4： | 1 |
| 20 | Role of tumor necrosis factor alpha in hyperthermia-induced apoptosis of human leukemia cells显示文摘 | Katschinski DM Robins HI Schad M | 1999 | Cancer Res1999，59，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员